Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 868 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dose Finding Study Clear all
Terminated Phase 1Phase 2 Interventional Results available

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

NCT04722601
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Obinutuzumab, CC-486
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02740972
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
NS-065/NCNP-01, Placebo
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
4 Years to 9 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Sacramento, California • Gainesville, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Results available

Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

NCT02728895
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

NCT05839600
View directory record Official record
Conditions
Solid Tumors
Interventions
BI 1821736
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 1839100 Improves Cough in People With Idiopathic Pulmonary Fibrosis or Progressive Pulmonary Fibrosis

NCT06360094
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Interventions
BI 1839100, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
18
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 1 Interventional

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
View directory record Official record
Conditions
Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
Interventions
ASN003 ascending doses, ASN003 MTD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 1 Interventional

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

NCT06247787
View directory record Official record
Conditions
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Recurrent Juvenile Myelomonocytic Leukemia, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome, Refractory Juvenile Myelomonocytic Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Hydrocortisone Sodium Succinate, Imetelstat, Leucovorin Calcium, Lumbar Puncture, Methotrexate
Procedure · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 18 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

NCT05923099
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD

NCT02038829
View directory record Official record
Conditions
COPD
Interventions
Placebo, SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg, SUN-101 50 mcg, Aclidinium
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
10
States / cities
Clearwater, Florida • Charlotte, North Carolina • Raleigh, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 1Phase 2 Interventional

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312
View directory record Official record
Conditions
Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
16
States / cities
Orange, California • Jacksonville, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 4 Interventional

An Open Label, Dose Finding Trial of Viagra for the Treatment of Neuropathic Pain (in Diabetes Mellitus)

NCT00194909
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
sildenafil (Viagra)
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2008 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study to Evaluate the Safety, Efficacy, & Tolerability of Multiple Doses of rAvPAL-PEG in Subjects With PKU

NCT00925054
View directory record Official record
Conditions
Phenylketonuria
Interventions
rAvPAL-PEG 0.001 mg/kg, rAvPAL-PEG 0.003 mg/kg, rAvPAL-PEG 0.01 mg/kg, rAvPAL-PEG 0.03 mg/kg, rAvPAL-PEG 0.1 mg/kg
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
16 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
11
States / cities
Aurora, Colorado • Decatur, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Results available

A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer

NCT02133742
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Axitinib, MK-3475
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
19
States / cities
Washington D.C., District of Columbia • Tampa, Florida • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients

NCT00900146
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canakinumab, Metformin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 74 Years
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
18
States / cities
Phoenix, Arizona • La Jolla, California • Los Gatos, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2012 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health

NCT05353322
View directory record Official record
Conditions
Sedentary Behavior, Cardiometabolic Risk Factors, Blood Pressure, Glucose
Interventions
Sedentary Break (Walking) Condition, Sitting (Control) Condition, Controlled Diet
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Phase II, Dose Finding Study of GTx-758

NCT01393119
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Glendale, Arizona • Phoenix, Arizona • La Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Results available

Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children

NCT01669642
View directory record Official record
Conditions
Abscess, Fracture
Interventions
Ketamine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 3 Interventional

A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How Safe it is

NCT04786873
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Macimorelin, Arginine, Clonidine
Drug · Diagnostic Test
Lead sponsor
AEterna Zentaris
Industry
Eligibility
2 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Greenwood Village, Colorado • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2024 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Finding Study In Subjects With Crow's Feet

NCT01951742
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1401, Vehicle
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
Miami, Florida • Pinellas Park, Florida • West Palm Beach, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

1-Octanol to Treat Essential Tremor

NCT00016679
View directory record Official record
Conditions
Essential Tremor
Interventions
1-Octanol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial of rPA-102 Vaccine in Healthy Adult Volunteers

NCT00100724
View directory record Official record
Conditions
Anthrax
Interventions
rPA102
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years to 55 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
12
States / cities
Torrance, California • Atlanta, Georgia • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2006 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Results available

Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer

NCT01347788
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment

NCT00002394
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Terbinafine hydrochloride
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Fort Lauderdale, Florida • Fort Myers, Florida • Tamarac, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 8:40 AM EDT
Not yet recruiting Not applicable Interventional

Focused Ultrasound for Behavioral Health

NCT07851038
View directory record Official record
Conditions
Depression, Anxiety, Obsessive Compulsive Disorder (OCD)
Interventions
ATTN201 head-worn focused ultrasound
Device
Lead sponsor
Attune Neurosciences Inc
Industry
Eligibility
22 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 8:40 AM EDT